Multiple autologous tumor-infiltrating lymphocyte (LM103 infusion) therapy combined with immune checkpoint inhibitor induces repeated tumor regression in a patient with aggressive mucosal melanoma: a case report and literature review

Tumor-infiltrating lymphocyte (TIL) therapy was approved as a one-dose treatment indicated for melanoma patients who have progressed on anti-PD-1 therapy. However, the majority of patients show only short-duration responses, highlighting the urgent need to explore multiple cycles of TIL therapy and...

Cijeli opis

Bibliografski detalji

Glavni autori:	Fenge Li, Yue Xu, Yupeng Wang, Ning Mu, Mei Liu, Weihong Feng, Yongming Xue, Shengnan Wu, Xinyi Wang, Gregory Lizee, Chunhua Ma
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-04-01
Serija:	Frontiers in Oncology
Teme:	clinical response cytokine secretion immune monitoring multiple TIL therapy tumor-infiltrating lymphocytes
Online pristup:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1789442/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!